Daniel Muthas

AstraZeneca, BioPharmaceuticals R&D
Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial.

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: August 08, 2025

Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial.

Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial.

Journal: RMD open

Published: May 20, 2025

FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma.

FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma.

Journal: ERJ open research

Published: February 07, 2025

Lung IL-13 gene signatures are associated with raised tissue eosinophils in COPD.

Lung IL-13 gene signatures are associated with raised tissue eosinophils in COPD.

Journal: Respiratory research

Published: October 09, 2024

NTHi killing activity is reduced in COPD patients and is associated with a differential microbiome.

NTHi killing activity is reduced in COPD patients and is associated with a differential microbiome.

Journal: Respiratory research

Published: September 25, 2024

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.

Journal: Annals of the rheumatic diseases

Published: December 20, 2023

Multiomics links global surfactant dysregulation with airflow obstruction and emphysema in COPD.

Multiomics links global surfactant dysregulation with airflow obstruction and emphysema in COPD.

Journal: ERJ open research

Published: July 26, 2022

Proteomic profiling of serum identifies a molecular signature that correlates with clinical outcomes in COPD.

Proteomic profiling of serum identifies a molecular signature that correlates with clinical outcomes in COPD.

Journal: PloS one

Published: May 12, 2022

Dysregulation of COVID-19 related gene expression in the COPD lung.

Dysregulation of COVID-19 related gene expression in the COPD lung.

Journal: Respiratory research

Published: January 28, 2021

Rare variant contribution to human disease in 281,104 UK Biobank exomes.

Rare variant contribution to human disease in 281,104 UK Biobank exomes.

Journal: Nature

Published: November 03, 2020

Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosis.

Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosis.

Journal: Communications biology

Published: September 10, 2020

MODifieR: an Ensemble R Package for Inference of Disease Modules from Transcriptomics Networks.

MODifieR: an Ensemble R Package for Inference of Disease Modules from Transcriptomics Networks.

Journal: Bioinformatics (Oxford, England)

Published: December 04, 2019

Showing 1-12 of 24

Last Updated: 09/26/2026